JP7369693B2 - てんかん性の疾患、障害、または病態の処置に使用するためのプロベネシド - Google Patents

てんかん性の疾患、障害、または病態の処置に使用するためのプロベネシド Download PDF

Info

Publication number
JP7369693B2
JP7369693B2 JP2020523047A JP2020523047A JP7369693B2 JP 7369693 B2 JP7369693 B2 JP 7369693B2 JP 2020523047 A JP2020523047 A JP 2020523047A JP 2020523047 A JP2020523047 A JP 2020523047A JP 7369693 B2 JP7369693 B2 JP 7369693B2
Authority
JP
Japan
Prior art keywords
acid
epilepsy
day
subject
probenecid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527172A (ja
JP2020527172A5 (enExample
Inventor
ロウチ，ナタリー
ドッシ，エレナ
フバーフェルド，ギレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Cite
Original Assignee
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Cite filed Critical Universite Paris Cite
Publication of JP2020527172A publication Critical patent/JP2020527172A/ja
Publication of JP2020527172A5 publication Critical patent/JP2020527172A5/ja
Application granted granted Critical
Publication of JP7369693B2 publication Critical patent/JP7369693B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020523047A 2017-07-13 2018-07-13 てんかん性の疾患、障害、または病態の処置に使用するためのプロベネシド Active JP7369693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305934.6 2017-07-13
EP17305934.6A EP3427729A1 (en) 2017-07-13 2017-07-13 Probenecid for use in treating epileptic diseases, disorders or conditions
PCT/EP2018/069092 WO2019012109A1 (en) 2017-07-13 2018-07-13 PROBENECID FOR USE IN THE TREATMENT OF EPILEPTIC DISEASES, DISORDERS OR DISORDERS

Publications (3)

Publication Number Publication Date
JP2020527172A JP2020527172A (ja) 2020-09-03
JP2020527172A5 JP2020527172A5 (enExample) 2021-08-12
JP7369693B2 true JP7369693B2 (ja) 2023-10-26

Family

ID=59384111

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020523047A Active JP7369693B2 (ja) 2017-07-13 2018-07-13 てんかん性の疾患、障害、または病態の処置に使用するためのプロベネシド

Country Status (6)

Country Link
US (2) US12318358B2 (enExample)
EP (2) EP3427729A1 (enExample)
JP (1) JP7369693B2 (enExample)
CN (2) CN111386107A (enExample)
CA (1) CA3070178A1 (enExample)
WO (1) WO2019012109A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128034B2 (en) 2020-03-11 2024-10-29 Iterum Therapeutics International Limited Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
TWI804037B (zh) * 2021-11-02 2023-06-01 長庚醫療財團法人高雄長庚紀念醫院 生酮飲食之評估系統及其運作方法
EP4505999A1 (en) 2023-08-07 2025-02-12 Panntherapi Probenecid formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US902695A (en) 1907-12-31 1908-11-03 Stasia B Staley Package-tie.
JPS586027A (ja) 1981-07-01 1983-01-13 住友電気工業株式会社 高圧ケ−ブルの接続部
GB2104078B (en) 1981-08-14 1985-01-23 London Polytech New aminoacid isomers, their production and their medicinal use
HUT40447A (en) 1984-03-29 1986-12-28 Sandoz Ag Process for preparing substituted alpha-amino acids and pharmaceutical compositions containing such compounds
CA1248531A (en) 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids
US4906621A (en) 1985-05-24 1990-03-06 Ciba-Geigy Corporation Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade
US4746653A (en) 1986-02-28 1988-05-24 Ciba-Geigy Corporation Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals
US4657899A (en) 1986-04-09 1987-04-14 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors
IE66149B1 (en) 1986-09-16 1995-12-13 Novo Nordisk As Quinoxaline compounds and their preparation and use
US4812458A (en) 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
US4705781A (en) 1986-10-08 1987-11-10 Giba-Geigy Corporation Method of treating cerebral ischemia using 4-(phosphono substituted lower alkyl or lower alkenyl)piperazine-2-carboxylic acids and salts, esters and amides thereof
GB8625941D0 (en) 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
IL84492A0 (en) 1986-11-21 1988-04-29 Ciba Geigy Ag Unsaturated phosphonic acids and derivatives
GB8703749D0 (en) 1987-02-18 1987-03-25 Sandoz Ltd Piperazinecarboxylic acid
US4761405A (en) 1987-03-04 1988-08-02 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid neurotransmitter receptors having increased potency
DK146787A (da) 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
PH27591A (en) 1987-08-04 1993-08-31 Ciba Geigy Ag A process for the manufacture of novel unsaturated amino acid compound
GB8719102D0 (en) 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
US4918064A (en) 1987-10-21 1990-04-17 G. D. Searle & Co. Phenyl glycines for use in reducing neurotoxic injury
NO179551C (no) 1987-11-10 1996-10-30 Novo Nordisk As Analogifremgangsmåte for fremstilling av terapeutisk virksomme kinoxalinforbindelser
GB8727792D0 (en) 1987-11-27 1987-12-31 Merck Sharp & Dohme Therapeutic agents
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US4968678A (en) 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
JPH0210544A (ja) 1988-06-29 1990-01-16 Canon Inc 光磁気記憶装置
EP0342558B1 (en) 1988-05-16 1994-02-02 G.D. Searle & Co. 2-amino-4,5-methyleneadipic acid compounds for treatment of CNS disorders
DK160941C (da) 1988-06-28 1991-10-21 Novo Nordisk As Kondenserede 2,3-dihydroxypyraziner, fremgangsmaade til deres fremstilling og farmaceutiske praeparater, hvori forbindelserne indgaar
GB8823605D0 (en) 1988-10-07 1988-11-16 Merck Sharp & Dohme Therapeutic agents
CA2000901A1 (en) 1988-10-21 1990-04-21 Alexis A. Cordi Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury
DK715888D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DK716188D0 (da) 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
US5187171A (en) 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US4902695A (en) 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
DE69029668T2 (de) 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US4902687A (en) 1989-03-27 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
ATE112282T1 (de) 1989-04-07 1994-10-15 Ciba Geigy Ag Ungesättigte aminodicarbonsäurederivate.
GB8908529D0 (en) 1989-04-14 1989-06-01 Merck Sharp & Dohme Therapeutic agents
US4960786A (en) 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
CA2025326C (en) 1989-09-19 2001-04-24 Jeffrey P. Whitten Nmda antagonists
EP0420806B1 (de) 1989-09-26 1995-07-05 Ciba-Geigy Ag Phosphonsäure, Verfahren zur Herstellung und Verwendung als Arzneimittelwirkstoff
DK0501378T3 (da) * 1991-02-28 1995-03-20 Merrell Dow Pharma NMDA-antagonister
ATE162075T1 (de) 1991-09-09 1998-01-15 Warner Lambert Co Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Brain Research Bulletin，1992年，Vol.28，pp.233-238
CNS & Neurological Disorders-Drug Targets，2013年，vol.12，pp.1050-1065
Neuropharmacology，2004年，vol.47，pp.916-925

Also Published As

Publication number Publication date
RU2020106762A3 (enExample) 2021-11-10
CN120478323A (zh) 2025-08-15
CN111386107A (zh) 2020-07-07
EP3651758A1 (en) 2020-05-20
JP2020527172A (ja) 2020-09-03
US12318358B2 (en) 2025-06-03
EP3427729A1 (en) 2019-01-16
US20250288544A1 (en) 2025-09-18
RU2020106762A (ru) 2021-08-13
WO2019012109A1 (en) 2019-01-17
US20200163916A1 (en) 2020-05-28
CA3070178A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US20250288544A1 (en) Probenecid for use in treating epileptic diseases, disorders or conditions
EP2389187B1 (en) Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
ES2710460T3 (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis múltiple
ES2952727T3 (es) Tratamiento de la enfermedad de Alzheimer en una población de pacientes particular
WO2009018368A1 (en) Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
US20220133652A1 (en) A formulation for improving seizure control
BRPI0618239A2 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico
JP7319421B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
US20250049790A1 (en) Treatment of neurological disorders
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
EP3096790B1 (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
RU2785842C2 (ru) Применение пробенецида для лечения эпилептических заболеваний, нарушений и состояний
ES3004543T3 (en) Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP2982382A1 (en) Compounds for preventing ototoxicity
KR20070085309A (ko) 신경변성 질환 치료에 사용하는 카바메이트 화합물
JP2006522084A (ja) アルツハイマー病治療のためのｇｈ分泌促進物質及びｐｄｅ４阻害剤の組み合わせ
EP4301351A1 (en) Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
JPWO2021156769A5 (enExample)
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
JP5714572B2 (ja) 精神障害およびその症状の治療のためのｋｃｎｑカリウムチャネル活性の調節方法
IE20130078A1 (en) Methods for using thalidomide and thalidomide analogues to maintain or increase muscle mass in treating sarcopenia
JP2021505668A (ja) 併用療法（睡眠障害およびｃｎｓ障害）において使用するためのｎｍｄａ受容体モジュレーター（ラパスチネル）の組合せ
KR20190054549A (ko) 말초신경의 나트륨-채널병증을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
ES2832549T3 (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210702

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231016

R150 Certificate of patent or registration of utility model

Ref document number: 7369693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150